

Increased *MET* and *HGF* gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

G Minuti¹, F Cappuzzo^{*1}, R Duchnowska^{2,12}, J Jassem^{3,12}, A Fabi⁴, T O'Brien⁵, AD Mendoza⁵, L Landi¹, W Biernat^{3,12}, B Czartoryska-Ar/ukowicz^{6,12}, T Jankowski^{7,12}, D Zuziak^{8,12}, J Zok^{9,12}, B Szostakiewicz^{3,12}, M Foszczyńska-Kłoda^{10,12}, A Tempnińska-Sza/ach^{11,12}, E Rossi¹ and M Varella-Garcia⁵

¹Department of Medical Oncology, Civil Hospital of Livorno, Istituto Toscano Tumori, Viale Alfieri 36, Livorno 57100, Italy; ²Department of Oncology, Military Institute of Medicine, 128 Szaserów Street, Warsaw 00-909, Poland; ³Department of Oncology and Radiotherapy, Medical University of Gdańsk, 3a M Skłodowskiej-Curie Street, Gdańsk 80-210, Poland; ⁴Department of Medical Oncology, National Cancer Institute Regina Elena, Via E Chianesi 53, RM 00144, Rome, Italy; ⁵Molecular Pathology Shared Resource, University of Colorado Cancer Center, 13001 E 17th Place, CO 80045, Aurora, Colorado, USA; ⁶Department of Oncology, Białystok Oncology Center, 47 Fabryczna Street, Białystok 15-047, Poland; ⁷Department of Oncology, Lublin Oncology Center, 7 Jaczewskiego Street, Lublin PL- 20090, Poland; ⁸Department of Oncology, Beskidy Oncology Center, 18 Liberation Street, Bielsko-Biała 43-300, Poland; ⁹Department of Oncology, Warmia and Masuria Oncology Center, 5 Oczapowskiego Street, Olsztyn 10-967, Poland; ¹⁰Department of Oncology, West Pomeranian Oncology Center, 55 Adama Mickiewicza Street, Szczecin 70-385, Poland; ¹¹Department of Oncology, District Hospital of Elbląg, 35 Komerińskiego Street, Elbląg 82-300, Poland

BACKGROUND: To investigate whether copy number gain of *MET* or hepatocyte growth factor (*HGF*) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC).

METHODS: We analysed 130 HER2-positive MBC treated with trastuzumab-based therapy. *MET* and *HGF* gene copy numbers (GCN) were assessed by fluorescence *in situ* hybridisation (FISH) in primary breast cancer samples. Receiver operating characteristic analysis was applied to find the best cutoff point for both *MET* and *HGF* GCN.

RESULTS: *MET* FISH-positive cases ($N=36$, mean ≥ 3.72) had a significantly higher trastuzumab failure rate (44.4% vs 16.0%; $P=0.001$) and a significantly shorter time to progression (5.7 vs 9.9 months; HR 1.74; $P=0.006$) than *MET* FISH-negative cases ($N=94$, mean < 3.72). Hepatocyte growth factor GCN was evaluated in 84 cases (64.6%). Receiver operating characteristic analysis identified 33 *HGF* FISH-positive patients (mean *HGF* GCN ≥ 3.01). *HGF* FISH-positive status was significantly associated with higher risk of failure (30.3% vs 7.8%; $P=0.007$) as compared with *HGF* FISH-negative cases ($N=51$, mean < 3.01). *MET* and *HGF* FISH-positive status was highly correlated ($P<0.001$) and combination of both biomarkers did not increase predictive value of either considered separately.

CONCLUSION: High GCNs of *MET* and *HGF* associate with an increased risk of trastuzumab-based therapy failure in HER2-positive MBC.

British Journal of Cancer (2012) 107, 793–799. doi:10.1038/bjc.2012.335 www.bjcancer.com

Published online 31 July 2012

© 2012 Cancer Research UK

Keywords: breast cancer; HER2-positive; *HGF*; *MET*

The human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor that belongs to the epidermal growth factor receptor (EGFR) family. Approximately 20–25% of breast cancers are characterised by HER2 protein overexpression or gene amplification, and such events are associated with poor prognosis (Slamon *et al*, 1987).

The humanised recombinant monoclonal antibody trastuzumab (Herceptin, Genentech, Inc., San Francisco, CA, USA) was the first HER2-targeting agent approved for clinical use in breast cancer (Carter *et al*, 1992). In HER2-overexpressing or -amplified (HER2-positive) breast cancer patients, large phase III trials demonstrated that trastuzumab in combination with chemotherapy was signi-

ficantly more effective than chemotherapy alone both in advanced disease and in adjuvant setting (Slamon *et al*, 2001; Piccart-Gebhart *et al*, 2005; Romond *et al*, 2005; Robert *et al*, 2006; Slamon *et al*, 2011). Although trastuzumab-based treatments represent today the standard approach for HER2-positive breast cancer, not all patients benefit from this therapy. In metastatic breast cancer (MBC) patients with high degree of HER2 expression, single-agent trastuzumab resulted in 35% response rate (Vogel *et al*, 2002), indicating that there is a considerable proportion of individuals potentially refractory to HER2 inhibition even in presence of the drug target. Moreover, one of the major clinical problems encountered with trastuzumab treatment is that MBC patients who initially respond to trastuzumab, show disease progression within 1 year from treatment initiation. A better knowledge of mechanisms responsible for primary and acquired resistance may improve prediction of trastuzumab sensitivity. Several mechanisms of resistance have been described to date, including co-expression of the truncated p95HER2 receptor (Scaltriti

*Correspondence: Dr F Cappuzzo; E-mail: f.cappuzzo@googlemail.com

¹²For the Central and East European Oncology Group (CEEEOG).

Received 29 March 2012; revised 28 June 2012; accepted 6 July 2012; published online 31 July 2012

et al, 2007), activation of the phosphatidylinositol-3-kinase (PTEN/PI3K/AKT signalling pathway) (Berns *et al*, 2007) and heterodimerisation with other growth factor receptors including MET (Shattuck *et al*, 2008), but their clinical relevance is still debatable.

MET oncogene, localised on chromosome 7 and encoding the dimeric tyrosine kinase receptor for hepatocyte growth factor (HGF), is involved in cell proliferation, survival and angiogenesis (Bottaro *et al*, 1991). MET-regulated invasive growth has a relevant role in cancer invasion and metastasis (Bocaccio and Comoglio, 2006). MET gene amplification has been described in many human cancers including lung (Tsao *et al*, 1998; Cappuzzo *et al*, 2009), gastric (Hara *et al*, 1998), oesophageal (Miller *et al*, 2006) and endometrial cancer (Samuelson *et al*, 2008), and correlates with aggressive disease and poor patient outcome (Graziano *et al*, 2011). In lung cancer, MET amplification is responsible for acquired resistance to anti-EGFR tyrosine kinase inhibitors in up to 20% of cases (Engelman *et al*, 2007). In breast cancer, MET and HGF overexpression correlates with short relapse-free and overall survival (OS) (Yamashita *et al*, 1994; Nagy *et al*, 1996; Yao *et al*, 1996; Jin *et al*, 1997; Edakuni *et al*, 2001; Kang *et al*, 2003). In a recent study, Raghav *et al* (2012) reported that high levels of MET protein expression was associated with poor prognosis in early breast cancer. Lindemann *et al* (2007) reported MET overexpression in 25% of HER2-positive breast tumours, supporting the hypothesis that both HER2 and MET receptors could synergise in promoting tumour growth. More recently, Shattuck *et al* (2008) showed that MET contributes to trastuzumab resistance, and a subset of HER2-positive breast cancer patients may benefit from combined inhibition of both HER2 and MET.

Based on previous data, in the current study we aimed to investigate whether MET and HGF gene copy numbers (GCN) are associated with trastuzumab sensitivity in HER2-positive MBC patients.

PATIENTS AND METHODS

Patient selection

This retrospective study was conducted in a consecutive series of 130 HER2-positive MBC patients treated with trastuzumab in combination with chemotherapy or as a single agent in 13 centres in Italy and Poland. The HER2 status was determined locally and was defined as positive in presence of gene amplification detected by fluorescence *in situ* hybridisation (FISH) or in presence of high degree of expression (3+) by immunohistochemistry according to criteria described elsewhere (Hammond *et al*, 2011). MET and HGF

GCN were evaluated on primary breast tumour tissue obtained at the time of surgery before any trastuzumab-based therapy. Main inclusion criteria adopted for patient selection included availability of primary breast cancer tumour tissue, possibility to verify the response according to RECIST criteria, and availability of clinical data including survival. The study was approved by the ethics committees of all local hospitals and was conducted in accordance with ethical principles stated in the most recent version of the Declaration of Helsinki or the applicable guidelines on good clinical practice, whichever represented the greater protection of the individuals.

Fluorescence *in situ* hybridisation analyses

Unstained 4–5 µm sections were subjected to a tri-colour FISH assay, using a probe cocktail including HGF sequences (RP11-554M24 labelled in Spectrum Gold), MET sequences (RP 11-95I20 labelled in Spectrum Red) and centromere 7 sequences (CEP7, labelled in Spectrum Green, Abbott Molecular, Denver, CO, USA). The FISH assays were performed according to previously described protocol (Cappuzzo *et al*, 2009), including pre-treatment with 2 × SSC at 75 °C and digestion with Proteinase K for 5–20 min each, co-denaturation at 85 °C for 15 min, hybridisation for approximately 36 h and rapid post-hybridisation washes with 2 × SSC/0.4 NP40. Signals were enumerated in at least 50 tumour nuclei per specimen, using epifluorescence microscope with single interference filters at the following excitation/emission wavelengths: 350/460 for blue, 492/530 for green, 530/580 for gold and 572/625 for red, as well as dual (red/green) and triple (blue, red, green) band pass filters. For each slide, the mean and s.d. of copy number per cell of each tested DNA sequence, the percentage of cells with ≤2, 3 and ≥4 copies of each target and the ratio of MET/CEP7 and HGF/CEP7 were calculated. For documentation, images were captured using a CCD camera and merged using dedicated software (Leica Microsystems, Denver, CO, USA) (Figure 1).

MET FISH analysis was successfully performed in all 130 cases. Fluorescence *in situ* hybridisation analysis of HGF was only performed in 84 cases (64.6%), as adequate material was not available in 46 cases.

Lack of additional tumour sections did not allow us to perform additional biomarker analyses.

Statistical analyses

The primary end point of the study was to assess whether increased MET and HGF GCNs affect sensitivity to trastuzumab in




Figure 1 Hybridisation with the probe mix MET (Spectrum Red) CEP7 (Spectrum Green) and HGF (Spectrum Gold) showing both MET and HGF low GCN in (A) and high GCN in (B). The color reproduction of this figure is available at the *British Journal of Cancer* online.

terms of failure rate. Patients were dichotomised into sensitive (complete or partial response and disease stabilisation) and refractory (evidence of progressive disease at the first imaging assessment). The cutoff for *MET* and *HGF* GCN discriminating between a positive or negative result was determined using a receiver operating characteristic analysis. Time to progression (TTP) was calculated from the date of first administration of trastuzumab to the date of progression or last assessment. Overall survival was calculated from the date of first administration of trastuzumab to the date of death or last contact. Differences in failure rate were compared by Fisher's exact test or χ^2 test. Time to progression, OS and the 95% confidence intervals for the groups with negative and positive biomarker were evaluated by survival analysis using Kaplan–Meier method (Kaplan and Meier, 1985), and compared using the log-rank test. Statistical significance was set at <0.05 for each analysis. Multivariable analysis was performed using logistic regression analysis with a step-down procedure method, with response considered as independent variable. The model was built only on clinical variable, which were significantly associated with response rate at bivariate analysis.

RESULTS

Patient characteristics

A total of 130 HER2-positive MBC patients were included in this analysis. The vast majority of patients ($N=109$, 83.8%) received trastuzumab in combination with chemotherapy in first-line setting ($N=82$, 63%), most frequently in association with taxanes (paclitaxel 32.3%, docetaxel 20.8%). The remaining 21 patients (16.1%) received single-agent trastuzumab (Table 1). In the entire study population, response rate, including complete and partial response was 49.2%, median TTP was 9.4 months (range: 8.3–10.5 months) and median OS was 28.3 months (range: 22.6–33.9 months).

MET FISH results

No *MET* gene amplification (defined as ratio mean *MET*/mean CEP 7 >2) was detected and median mean *MET* GCN was 2.96 (range, 1.66–8.40 copies per cell). In two cases, an equivocal range (*MET*/CEP 7 ratio between 1.8 and 2) was observed (*MET*/CEP 7 ratio of 1.84 and 1.82, respectively). As illustrated in Figure 2A, receiver operating characteristic analysis identified a mean of 3.72 *MET* GCN as the optimal cutoff value for discriminating between sensitive and refractory patients. A total of 36 cases (27.7%) had mean *MET* ≥ 3.72 (*MET* FISH positive) and 94 cases (72.3%) had mean *MET* <3.72 (*MET* FISH negative). As shown in Table 2, *MET* FISH status was not associated with any clinical or biological characteristic. However, *MET* FISH-positive patients had a significantly higher failure rate (44.4% vs 16.0%; $P=0.001$) and a significantly shorter TTP (median 5.7 vs 9.9 months; HR: 1.74; 95% CI 1.16–2.62; $P=0.006$) than *MET* FISH-negative patients (Figure 3A). *MET* FISH-positive patients had slightly shorter OS than *MET* FISH-negative patients (median 26.4 vs 29.1 months), but the difference was not statistically significant (HR: 1.12; 95% CI 0.65–1.93; $P=0.681$; Figure 3B). Importantly, a difference between *MET* FISH positive and *MET* FISH negative was observed in the small subgroup ($N=21$) of individuals treated with trastuzumab alone. In such subgroup, failure rate (20.0% vs 50.0%) and TTP (median 9.5 vs 1.9 months) were in favour of *MET* FISH-negative patients, even if, probably because of the small numbers, differences were not statistically significant ($P=0.3$ and $P=0.2$, respectively).

Fluorescence in situ hybridisation results of HGF

Median mean *HGF* GCN was 2.80 (range, 1.14–6.90 copies per cell). As illustrated in Figure 2B, receiver operating characteristic

Table 1 Patient characteristics

Characteristics	Total	%
Total no. of patients	130	100
Median age, years (range)	55 (33–80)	
<i>Menopausal status</i>		
Available/not available	104/26	80/20
Premenopausal/postmenopausal	18/86	17.3/82.7
<i>Histology</i>		
Invasive ductal carcinoma	114	87.7
Invasive lobular carcinoma	8	6.1
Other types	8	6.1
<i>Grade</i>		
2	47	36.1
3	68	52.3
Not defined	15	11.5
<i>Hormonal status (IHC)</i>		
ER value $\geq 10\%$	52	40
PgR value $\geq 10\%$	43	33
<i>Mib1/Ki67</i>		
Available/not available	47/83	36.1/63.8
Value $\geq 10\%$	44	93.6
<i>HER2+ (IHC/FISH)</i>		
IHC 3+ and FISH not done	76	58.5
IHC 2+ and FISH amplified	6	4.6
IHC 3+ and FISH amplified	48	36.9
<i>Treatment</i>		
Trastuzumab monotherapy	21	16.1
Trastuzumab with chemotherapy	109	83.8
<i>Line of treatment</i>		
First line	82	63
Second line	37	28.5
Third or subsequent lines	11	8.5
<i>Drug combined with trastuzumab</i>		
None	21	16.1
Paclitaxel	42	32.3
Docetaxel	27	20.8
Vinorelbine	25	19.2
Other	15	11.5

Abbreviations: MBC = metastatic breast cancer; ER = oestrogen receptor; PgR = progesterone receptor; HER2+ = human epidermal growth factor receptor 2 positive (overexpression and/or amplification); IHC = immunohistochemistry; FISH = fluorescent *in situ* hybridisation.

analysis identified a mean of 3.01 *HGF* GCN as the optimal cutoff value for discriminating between sensitive and refractory patients. This cutoff split 33 cases (39.3%) as *HGF* FISH positive (mean *HGF* GCN ≥ 3.01) and 51 cases (60.7%) as *HGF* FISH negative (mean *HGF* GCN <3.01). As summarised in Table 3, *HGF* FISH status was not associated with any clinical characteristics, whereas there was a strong association between *HGF* and *MET* FISH status ($P<0.001$): all *MET* FISH-positive cases resulted *HGF* FISH positive and all *HGF* FISH-negative cases were *MET* FISH negative. Patients who were *HGF* FISH positive had a significantly higher failure rate (30.3% vs 7.8%; $P=0.007$) and a non-significantly shorter TTP (median 9.9 vs 10.5 months, HR 1.10 95% CI 0.70–1.74, $P=0.665$) than *HGF* FISH-negative patients (mean <3.01 ; Figure 4A). Patients who were *HGF* FISH positive had a not statistically significant longer OS (median 35.2 vs 26.1 months, HR 0.83 95% CI 0.44–1.56, $P=0.567$) than *HGF* FISH-negative patients (Figure 4B).




Figure 2 (A) Receiver operating characteristic (ROC) analysis identified a mean of 3.72 *MET* GCN as the optimal cutoff value discriminating sensitive and resistant population, associated with a sensitivity of 51.6% and a specificity of 79.8%. AUC (area under the curve) value was 0.679. (B) ROC analysis identified a mean of 3.01 *HGF* GCN as optimal cutoff value, associated with a sensitivity of 71.4% and a specificity of 67.1%. AUC (area under the curve) value was 0.663.

Table 2 Association between *MET* gene copy number and clinical and biological characteristics in HER2-positive metastatic breast cancer patients (N = 130)

Characteristic	<i>MET</i> FISH + (N/%)	<i>MET</i> FISH - (N/%)	P-value
All	36/27.7	94/72.3	
Age \geq 55 years	17/47.2	47/50.0	0.777
Age < 55 years	19/52.8	47/50.0	
Premenopausal	6/19.4	12/16.4	0.719
Postmenopausal	25/80.6	61/83.6	
Invasive ductal carcinoma	33/91.7	81/86.2	0.554
Other histology	3/8.3	13/13.8	
Grade 2	9/29.0	38/45.2	0.117
Grade 3	22/71.0	46/54.8	
IHC ER value \geq 10%	15/41.7	37/39.4	0.810
IHC ER value < 10%	21/58.3	57/60.6	
IHC PgR value \geq 10%	12/33.3	31/33.0	0.969
IHC PgR value < 10%	24/66.7	63/67.0	
Mib1/Ki67 value \geq 10%	35/97.2	92/97.9	1.000
Mib1/Ki67 value < 10%	1/2.8	2/2.1	

Abbreviations: *MET* = mesenchymal-epithelial transition factor; HER2 = human epidermal growth factor receptor 2; ER = oestrogen receptor; PgR = progesterone receptor; IHC = immunohistochemistry; FISH = fluorescent *in situ* hybridisation.

MET/HGF FISH combination

To further investigate the impact of combined *MET* and *HGF* GCNs, we analysed the outcome of the 84 patients in whom both biomarkers were assessable. As illustrated in Table 4, overall results confirmed that failure rate was significantly lower in the population negative for both *MET* and *HGF* ($P = 0.007$), with the percentage of progressing patients not significantly different than that detected with a single biomarker assay (failure rate: 7.8% in *MET* and *HGF* negative, 7.8% in *HGF* negative only and 16.0% in *MET* negative only).

Univariate and multivariate analysis

To define which variables were predictive of trastuzumab sensitivity, clinical and biological characteristics, such as age (<55 vs >55 years), menopausal status (pre vs post), grade (2 vs 3), oestrogen receptor status (<10% vs >10%), progesterone

receptor status (<10% vs >10%), proliferative activity (Mib1 <10% vs >10%), *MET* GCN (<3.72 vs >3.72) and *HGF* GCN (<3.01 vs >3.01) were evaluated in a univariate analysis, using trastuzumab failure rate as end point. Variables found significant in the univariate analysis (*MET* and *HGF* GCN) were included in the multivariate model. Because of the strong correlation between *MET* and *HGF*, multivariable model did not include both biomarkers at the same time. When *MET* was excluded, increased GCN of *HGF* resulted in a odds ratio of 5.87 (95% CI: 1.21–28.39, $P = 0.028$). When *HGF* was not included, increased GCN of *MET* resulted in a odds ratio of 6.02 (95% CI: 2.24–16.8, $P < 0.001$).

DISCUSSION

The present study, the first evaluating the role of *MET* and *HGF* GCN in a large cohort of HER2-positive MBC patients treated with trastuzumab-based therapy, provides important evidence for the critical role of HGF/MET signalling pathway for sensitivity to anti-HER2 agents. Increased *MET* or *HGF* GCNs were detected in approximately one-fourth cases of HER2-positive breast cancer and were significantly associated with higher risk of treatment failure, supporting a role of anti-*MET* strategies in breast cancer. Predictive value of *MET* and *HGF* GCN was similar and combining both biomarkers did not increase sensitivity of the assay.

MET is a plasma membrane protein that relays signals from the extracellular environment into the cytoplasm, activated when its extracellular domain binds to HGF, also known as scatter factor. Recent data demonstrated that increased *MET* GCN represents a negative prognostic factor in human malignancies including lung (Cappuzzo *et al*, 2009) and gastric cancer (Graziano *et al*, 2011). Preclinical and limited clinical data showed that *MET* amplification is an event responsible for resistance to agents interfering with the EGFR family. In lung cancer, two studies demonstrated that *MET* amplification occurs in approximately 15–20% of EGFR-mutant non-small-cell lung cancers with acquired resistance to the reversible EGFR tyrosine kinase inhibitors, gefitinib or erlotinib (Bean *et al*, 2007; Engelman and Jänne, 2008). In non-small-cell lung cancer, combination of anti-*MET* agents with anti-EGFR tyrosine kinase inhibitors (EGFR-TKIs) seems to be one of the most promising strategies to overcome acquired resistance to such agents (Engelman *et al*, 2007). Although in breast cancer *MET* is generally not focally amplified (Shattuck *et al*, 2008), recent studies




Figure 3 Time to progression (**A**) and survival (**B**) in MET FISH-positive and -negative patients, according to the cutoff of 3.72 GCN identified with the receiver operating characteristic (ROC) analysis. MET FISH-positive patients (N=36, 27.7%) had a significantly shorter time to progression (median 5.7 vs 9.9 months, HR 1.74; P=0.006) and a non-significant shorter survival (median 26.4 vs 29.1 months, HR: 1.12; P=0.681) than MET FISH-negative (N=94, 72.3%).

Table 3 Association between HGF gene copy number and clinical and biological characteristics in HER2-positive metastatic breast cancer patients (N=84)

Characteristic	HGF FISH + (N/%)	HGF FISH - (N/%)	P-value
All	33/39.3	51/60.7	
Age ≥55 years	17/51.5	26/51.0	0.962
Age <55 years	16/48.5	25/49.0	
Premenopausal	0	4/11.1	0.287
Postmenopausal	22/100	32/88.9	
Invasive ductal carcinoma	28/84.8	43/84.3	0.947
Other histology	5/15.2	8/15.7	
Grade 2	9/32.1	23/51.1	0.112
Grade 3	19/67.9	22/48.9	
IHC ER value ≥ 10%	13/39.4	19/37.3	0.844
IHC ER value < 10%	20/60.6	32/62.7	
IHC PgR value ≥ 10%	9/27.3	17/33.3	0.557
IHC PgR value < 10%	24/72.7	34/66.7	
MiB1/Ki67 value ≥ 10%	33/100	50/98.0	1.000
MiB1/Ki67 value < 10%	0	1/2.0	
MET FISH +	21/63.6	0	<0.001
MET FISH -	12/36.4	51/100	

Abbreviations: HGF = hepatocyte growth factor; FISH = fluorescent *in situ* hybridisation; MET = mesenchymal-epithelial transition factor; HER2 = human epidermal growth factor receptor 2; ER = oestrogen receptor; PgR = progesterone receptor; IHC = immunohistochemistry.

demonstrated a central role of MET in trastuzumab resistance. Shattuck *et al* (2008) showed in a cell line model that attenuation of MET activity leads to sensitisation to trastuzumab, whereas MET activation protects cells from the growth inhibitory effects of trastuzumab by preventing trastuzumab-induced p27 induction. In addition, they showed that MET is co-expressed along with HER2 in HER2-overexpressing breast cancer cells and HER2-positive breast cancer samples. Liu *et al* (2009) showed that high MET expression is associated with short progression-free survival in HER2-positive MBC patients treated with lapatinib, an irreversible EGFR and HER2 inhibitor. Our findings are in agreement with previous studies confirming that MET amplification is generally absent in breast cancer and that high MET GCN increases the risk of treatment failure (Shattuck *et al*, 2008). Response and TTP favoured patients

with no MET GCN gain, both in patients treated with trastuzumab plus chemotherapy and in patients treated with trastuzumab alone, supporting the potential therapeutic impact of anti-MET agents in MBC, particularly in combination with anti-HER2 agents.

Recently, Previdi *et al* (2012) showed that ARQ 197 (tivantinib), a c-MET inhibitor, significantly delays the onset and progression of bone metastases in *in vitro* and *in vivo* models, strongly suggesting that targeting c-MET may have therapeutic value in the treatment of MBC. In another study, Liu *et al* (2011) characterised MET and HER expression and signalling in a panel of human tumour cell lines and demonstrated the differential susceptibility of these cell lines to single agents or combinations of foretinib, a multi-kinase MET inhibitor, with HER-targeted agents, erlotinib or lapatinib. Interestingly, MET-amplified lines with EGFR or HER2 amplification were more sensitive to the combination of foretinib with lapatinib or erlotinib. Overall, these data suggest that therapy including a combination of anti-MET and anti-HER-targeted agents should be tested as a treatment option in HER2-positive patients with MET-amplified or -overexpressing tumours. The idea of combining trastuzumab with other targeted agents is not a new concept in breast cancer, as demonstrated in recent studies comparing trastuzumab with the combination of trastuzumab and pertuzumab, a novel anti-HER2 monoclonal antibody (Baselga *et al*, 2012; Gianni *et al*, 2012) or single-agent lapatinib with the association of trastuzumab and lapatinib in trastuzumab-refractory patients (Blackwell *et al*, 2010).

Another interesting finding in our study was the strong association of MET and HGF GCN. To the best of our knowledge, this is the first study reporting such association in breast cancer. Moreover presence of increased GCN of both MET and HGF in the same tumours explains why a single test was equally predictive than the combination of both assays. Although MET activation can either occur through ligand-independent or ligand-dependent mechanisms (Kang *et al*, 2003), our findings suggest that probably ligand-dependent MET activation could represent a relevant mechanism in HER2-positive breast cancer, indicating a potential role for anti-MET monoclonal antibodies in breast cancer. In a recent study, Xie *et al* (2012) demonstrated that HGF autocrine expression correlated with phospho-MET levels in HGF autocrine cell lines and these cell lines showed high sensitivity to MET inhibition. Our findings together with that of Xie *et al* (2012) data suggest that MBC patients with high HGF and MET levels could result particularly sensitive to MET therapeutics.




Figure 4 Time to progression (**A**) and survival (**B**) in HGF FISH-positive and -negative patients, according to the cutoff of 3.01 GCN identified with the receiver operating characteristic (ROC) analysis. HGF FISH-positive patients ($N = 33$, 39.3%) had a not significant shorter time to progression (median 9.9 vs 10.5 months, HR 1.10; $P = 0.665$) and a longer, not statistically significant, survival (median 35.2 vs 26.1 months, HR 0.83; $P = 0.567$) than HGF FISH-negative patients ($N = 51$, 60.7%).

Table 4 Outcome according to MET and HGF GCN

Biomarker	N	Failure		TTP (months)	OS (months)
		N	rate (N/%)		
A	MET+/HGF+	21	6/28.6	9.2	26.4
B	MET+/HGF-	0	—	—	—
C	MET-/HGF+	12	4/33.3	10.3	48.8
D	MET-/HGF-	51	4/7.8	10.5	26.1
P-value	A vs C		1.0	0.2	0.4
	A vs D		0.054	0.2	0.9
	A + C vs D		0.007	0.7	0.6

Abbreviations: TTP = time to progression; OS = overall survival; MET = mesenchymal-epithelial transition factor; HGF = hepatocyte growth factor.

In conclusion, this large retrospective study showed that HGF/MET signalling pathway interferes with trastuzumab-based therapy sensitivity in HER2-positive MBC. These data,

together with previous preclinical and clinical studies support further expansion of related studies and clinical development of anti-MET agents in combination with anti-HER2 compounds in HER2-positive MBC.

ACKNOWLEDGEMENTS

This work was supported by the Italian Association for Cancer Research (AIRC) (IG9425 to FC and LL), Associazione Oncologia Traslazionale (AOT) (to FC) and the National Cancer Institute (P30-CA46934). We are indebted to the pathology department of Milan University for technical support.

Conflict of interest

The authors declare no conflict of interest.

REFERENCES

- Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med* **366**: 109–119
- Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci USA* **104**: 20932–20937
- Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell* **12**: 395–402
- Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with erbB2-positive, trastuzumab-refractory metastatic breast cancer. *J Clin Oncol* **28**: 1124–1130
- Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. *Nat Rev Cancer* **6**: 637–645
- Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmieciak TE, Vande Woude GF, Aaronson SA (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science* **251**: 802–804
- Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammasio M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M (2009) Increased MET gene copy number negatively affects survival of surgical resected non-small cell lung cancer. *J Clin Oncol* **27**: 1667–1674
- Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. *Proc Natl Acad Sci USA* **89**: 4285–4289
- Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K (2001) Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. *Pathol Int* **51**: 172–178
- Engelman JA, Jänne PA (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *Clin Cancer Res* **14**: 2895–2899
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* **316**: 1039–1043

- Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol* 13: 25–32
- Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M (2011) Genetic activation of the MET Pathway and prognosis of patients with high-risk, radically resected gastric cancer. *J Clin Oncol* 29: 4789–4795
- Hammond ME, Hayes DF, Wolff AC (2011) Clinical notice for American Society of Clinical Oncology-College of American Pathologists Guideline recommendations on ER/PgR and HER2 testing in breast cancer. *J Clin Oncol* 29: e458
- Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence *in situ* hybridization. *Lab Invest* 78: 1143–1153
- Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID, Rosen EM (1997) Expression of scatter factor and c-met receptor in benign and malignant breast tissue. *Cancer* 79: 749–760
- Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL (2003) Tissue microarray analysis of hepatocyte growth factor/met pathway components reveals a role for met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. *Cancer Res* 63: 1101–1105
- Kaplan EL, Meier P (1985) Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53: 457–481
- Lindemann K, Resau J, Nährig J, Kort E, Leuser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N (2007) Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. *Histopathology* 51: 54–62
- Liu L, Shi H, Liu Y, Anderson A, Peterson J, Greger J, Martin AM, Gilmer TM (2011) Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. *Mol Cancer Ther* 10: 518–530
- Liu Y, Liu L, Shi H, Greger JG, Jackson KD, Marty-Ethgen P, Gilmer TM, Martin A (2009) cMET expression in HER2+ MBC patients with first-line lapatinib (L) treatment. *J Clin Oncol* 27: 15s (abstract 1073)
- Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW, Beer DG (2006) Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. *Oncogene* 25: 409–418
- Nagy J, Curry GW, Hillan KJ, McKay IC, Mallon E, Purushotham AD, George WD (1996) Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. *Surg Oncol* 5: 15–21
- Piccant-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Grotzer V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 353: 1659–1672
- Previdi S, Abbadessa G, Dalò F, France DS, Brogginini M (2012) Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor Tivantinib (ARQ 197) and shRNA c-MET knockdown. *Mol Cancer Ther* 11: 214–223
- Raghav KP, Wang W, Liu S, Chavez-Macgregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM (2012) cMET and phospho-cMET protein levels in breast cancers and survival outcomes. *Clin Cancer Res* 18(8): 2269–2277
- Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodun D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. *J Clin Oncol* 24: 2786–2792
- Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 353: 1673–1684
- Samuelson E, Levan K, Adamovic T, Levan G, Horvath G (2008) Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence *in situ* hybridization. *Cancer Genet Cytogenet* 181: 25–30
- Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. *J Natl Cancer Inst* 99: 628–638
- Shattuck DL, Miller JK, Carraway 3rd KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. *Cancer Res* 68: 1471–1477
- Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER-2 positive breast cancer. *N Engl J Med* 365: 1273–1283
- Slamon DJ, Clark GM, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235: 177–182
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 344: 783–792
- Tsao MS, Liu N, Chen JR, Pappas J, Ho J, To C, Viallet J, Park M, Zhu H (1998) Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancer. *Lung Cancer* 20: 1–16
- Vogel CL, Cobleigh MA, Tripathy D, Guthel JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 20: 719–726
- Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF (2012) Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. *Proc Natl Acad Sci USA* 109: 570–575
- Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, Shin S (1994) Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. *Cancer Res* 54: 1630–1633
- Yao Y, Jin L, Fuchs A, Joseph A, Hastings HM, Goldberg ID, Rosen EM (1996) Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. *Am J Pathol* 149: 1707–1717

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.